Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
J&J, Achillion Join For Hepatitis Drugs
by Michael McCoy
May 25, 2015
| A version of this story appeared in
Volume 93, Issue 21
Johnson & Johnson’s Janssen Pharmaceuticals unit has agreed to license hepatitis C drug assets from Achillion Pharmaceuticals, a developer of small-molecule drugs for infectious diseases. Janssen will invest $225 million in Achillion stock plus up to $1.1 billion in potential development, regulatory, and sales milestone payments. Achillion’s lead compound, ACH-3102, is a second-generation NS5A inhibitor now in Phase II clinical trials. J&J already markets the older treatment Olysio, but the firm isn’t a player in the newer all-oral market.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter